© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
Reactions to the emergence of novel immunotherapy agents for treatment of bladder cancer, including increased administration in community urology practices, and recommendations for sequencing newer therapies into treatment algorithms.
January 14th 2022
The current incidence of bladder cancer diagnoses and most common symptoms that newly diagnosed patients present with.
The types of healthcare professionals who may play a role in evaluating and diagnosing bladder cancer.
January 21st 2022
Administration of systemic therapy and management of side effects in patients with bladder cancer.
Elements that are critical to ensuring that patients with bladder cancer are managed appropriately by various healthcare professionals who will likely interact with patients and their family throughout the cancer journey.
February 9th 2022
Types of educational resources available to support patients with bladder cancer as recommended by urologists and medical oncologists.
An overview of treatment guidelines available to support urologists and medical oncologists who manage patients with bladder cancer.
February 16th 2022
Frontline treatment approaches recommended by urologists and medical oncologists for patients with non-metastatic muscle-invasive bladder cancer.
First-line treatment options available for patients with high-risk non-muscle invasive bladder cancer and variables that affect treatment decisions.
February 23rd 2022
The role of adjuvant therapy in nonmetastatic muscle invasive bladder cancer, and an overview of promising novel therapies in the treatment pipeline.
Types of patients with muscle invasive bladder cancer who may be candidates for a watch-and-wait approach.